FY2025 EPS Estimates for Genmab A/S Boosted by William Blair

Key Points

• William Blair has increased its FY2025 earnings per share (EPS) estimate for Genmab A/S to $1.73, up from the prior estimate of $1.72, surpassing the consensus estimate of $1.45 per share.
• Recent earnings results showed Genmab A/S reported $0.54 EPS for the last quarter, exceeding consensus estimates and achieving a net margin of 37.53%.
• Analysts have a consensus rating of "Moderate Buy" for Genmab's stock, with a target price set at $40.00 following a mix of upgrades and downgrades from various firms.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued on Monday, September 29th. William Blair analyst M. Phipps now expects that the company will earn $1.73 per share for the year, up from their previous estimate of $1.72. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.15. The firm had revenue of $925.00 million for the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. Genmab A/S has set its FY 2025 guidance at EPS.

Several other equities research analysts also recently issued reports on GMAB. Wall Street Zen upgraded Genmab A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 26th. HC Wainwright increased their target price on Genmab A/S from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday, August 15th. Zacks Research cut shares of Genmab A/S from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 19th. Truist Financial upped their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Finally, Guggenheim raised shares of Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price target on the stock in a report on Tuesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.00.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $30.67 on Wednesday. The company has a market cap of $19.68 billion, a P/E ratio of 15.41, a P/E/G ratio of 1.68 and a beta of 0.93. The stock's fifty day moving average price is $25.29 and its two-hundred day moving average price is $22.19. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $30.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Headlands Technologies LLC grew its stake in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Osaic Holdings Inc. grew its stake in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock valued at $33,000 after buying an additional 440 shares during the last quarter. CWM LLC grew its stake in shares of Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company's stock valued at $37,000 after buying an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares during the last quarter. Finally, AlphaCore Capital LLC bought a new position in shares of Genmab A/S during the second quarter valued at about $44,000. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.